III-GLP-R

Retatrutide is a first-in-class triple agonist that simultaneously activates three key metabolic hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. This triple mechanism produces synergistic effects on appetite suppression, energy expenditure, and glucose metabolism that exceed single or dual agonists.

The GLP-1 component reduces appetite and slows gastric emptying; GIP enhances insulin secretion and may support fat metabolism; glucagon receptor activation increases energy expenditure and promotes fat oxidation. With an extended half-life of approximately 6 days, retatrutide enables convenient once-weekly dosing while maintaining therapeutic levels.

In clinical trials, participants receiving 12 mg weekly retatrutide lost an average of 24% of their body weight over 48 weeks. In adults with type 2 diabetes, retatrutide (up to 12 mg weekly) achieved approximately 17% weight loss at 36 weeks alongside HbA1c reductions of approximately 2.0% compared to placebo. A 2025 meta-analysis of three trials (878 participants) confirmed retatrutide achieved significantly greater weight reduction than placebo (mean difference approximately 14% of body weight) with no significant increase in overall adverse events.